News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KAI Pharmaceuticals, Inc. Announces Advancement of KAI-4169 Clinical Program into a Phase 2 Trial



3/14/2011 10:03:31 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD). The Phase 2 study is a double-blind, randomized, placebo-controlled, multiple ascending dose study to assess the safety, tolerability and efficacy of multiple intravenous (IV) doses of KAI-4169 administered during hemodialysis in patients with SHPT.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES